Cargando…
Use of M-M-R II outside of the routinely recommended age range – a systematic literature review
M-M-R®(II) (M-M-R II) is routinely used in many countries at 12–15 months with a second dose at 4 to 6 years of age. However, the vaccine may need to be administered at other ages due to delays in the immunization schedule or in certain situations such as outbreaks or international travel. A systema...
Autores principales: | Pawaskar, Manjiri, Schmidt, Elvira, Marshall, Gary S., Fergie, Jaime, Richardson, Elizabeth, Saldutti, Louise Parks, Li, Se, Neumann, Monika, Koller, Linnea, Kuter, Barbara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920138/ https://www.ncbi.nlm.nih.gov/pubmed/34128759 http://dx.doi.org/10.1080/21645515.2021.1933874 |
Ejemplares similares
-
1390. Effectiveness of M-M-R(®) II in outbreaks - a systematic literature review of real-world observational studies
por: Li, Se, et al.
Publicado: (2020) -
ASVAC2022 : 8(th) Asian Vaccine Conference
por: Galagoda, Geethani C. S., et al.
Publicado: (2023) -
Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases
por: Van den Steen, Peter, et al.
Publicado: (2023) -
Mumps-specific antibody persistence in children aged 3–7 years immunized with two doses of mumps-containing vaccines: A prospective cohort study in Jiangsu Province, China
por: Sun, Jinfang, et al.
Publicado: (2023) -
Public health impact of herpes zoster vaccination on older adults in Hong Kong
por: Chan, Paul K. S., et al.
Publicado: (2023)